Lipopolysaccharide (LPS) is known to protect mice against the lethal effects of tumor growth (2, (6) (7) (8) (9) (10) . The components of the mechanism operative in the tumor-protective role of LPS in vivo are currently unknown, but several studies have shown that cultured macrophages activated with LPS can lyse tumor cells (1, 5) . Other studies on the in vitro activation of macrophages by LPS indicated that activation results in the liberation of factor(s) that can lyse malignant cells or inhibit their proliferation (3) , but which have no effect on normal cells (4) . We recently demonstrated that in vivo LPS-stimulated peritoneal cells can be used to adoptively transfer antitumor allograft resistance to syngeneic recipients (2) . Evidence was presented to indicate that the LPS had no direct inhibitory effect on the tumor cells, nor was any residual LPS present in the cell preparations which transferred such protection.
In the present paper, data are presented which suggest that LPS-induced tumor allograft destruction is mediated by a population of adherent peritoneal cells Mice were subjected to whole-body irradiation generated by a cesium-137 irradiator with a midphantom dose rate of 108 rads/m in air. Animals received either 330 rads (sublethal) or 660 rads (lethal) 2 days prior to the inoculation of 4 x 103 TA3-Ha cells and 1 day prior to treatment with LPS or saline. Certain groups of irradiated mice were reconstituted 24 h after irradiation by the intravenous (tail vein) injection of 6 x 107 nonadherent spleen cells and by the i.p. injection of bND, Experiments not done at these ratios.
c Chi-square with the Yates correction. h Chi-square with the Yates correction. The P value compares groups 2 and 3. No significant differences between groups 1 and 3. untreated mice, whereas the PC obtained from control, saline-injected mice were ineffective. From Table 1 it is apparent that the removal of adherent cells from LPS-stimulated PC prevents this transfer. Table 2 shows that 660 rads of whole-body irradiation 1 day before LPS injection abrogated the ability of LPS to prevent tumor growth. All mice receiving just irradiation survived until at least day 24, whereas those with tumor cells succumbed to the effect of tumor growth by day 17. This experiment was modified to decrease radiation-induced host cell damage. This involved utilizing a nonlethal dose of 330 rads, which temporarily suppresses lymphoid cell function as verified by the temporary reduction in the ability of irradiated mice to mount a humoral immune response to sheep erythrocytes. TableNOTES 1035 venously with nonadherent spleen cells and i.p. with nonadherent PC from syngeneic donors, then immediately injected with 20 ,ug of LPS i.p., partial protection against an i.p. tumor challenge was restored (Table 4) .
On the basis of the results presented in Tables  2 and 3 , it is clear that LPS cannot initiate events that lead to tumor allograft rejection without the presence of an inmunocompetent radiosensitive cell population. Moreover, the data in Table 1 imply the need for adherent cells, presumably macrophages, for the LPS-induced antitumor effect. Table 4 demonstrated that a nonadherent lymphoid cell population from either the spleen or peritoneum was required for LPS-mediated rejection of the tumor allograft. However, since these cells from LPSstimulated donors are not capable by themselves of adoptively transferring protection to normal recipients, they must function in an accessory role in in vivo LPS-initiated tumor protection. It is presently unknown whether the inability to fully restore LPS-induced tumor rejection by nonadherent cells (Table 4 , group 3) reflects an inappropriately low number of transferred cells, or whether other systems not restored by such transfers are operative. Nevertheless, it would appear that the LPS-initiated rejection of the TA3-Ha tumor allograft requires the cooperation of at least two cell types in vivo, one a radiosensitive nonadherent lymphoid cell and the other an adherent cell, presumably a macrophage. However, the participation of additional mechanisms, such as specific immunological responses, or the elaboration of soluble substances, as previously described in this system (2), have not been excluded.
